Edoxaban Demonstrates Non-Inferiority to Warfarin in Stroke Prevention in AF Patients: Daiichi Sankyo

Late-breaking clinical trial session at AHA Scientific Sessions Daiichi Sankyo’s direct factor Xa inhibitor Lixiana (edoxaban), which the company hopes will become its next mainstay product, demonstrated non-inferiority in its efficacy to conventional warfarin in the multinational PIII ENGAGE AF-TIMI...read more